Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760004 | 0.78 | FFAR4 (0.43) | FFAR4CSF1RSMO | |
| SCHEMBL21246199 | 0.78 | OPRM1 (0.39) | FFAR4CSF1RSMO | |
| SCHEMBL12918279 | 0.78 | OPRM1 (0.40) | FFAR4CSF1RSMO | |
| SCHEMBL15573387 | 0.78 | OPRM1 (0.39) | FFAR4CSF1RSMO | |
| SCHEMBL30436488 | 0.78 | OPRM1 (0.39) | FFAR4CSF1RSMO | |
| SCHEMBL5519697 | 0.78 | FFAR4 (0.34) | FFAR4CSF1RSMO | |
| SCHEMBL21223187 | 0.76 | FFAR4 (0.33) | FFAR4CSF1RSMO | |
| SCHEMBL20898739 | 0.75 | MAP3K12 (0.40) | FFAR4CSF1RSMO | |
| SCHEMBL21610806 | 0.74 | CHRNA7 (0.33) | FFAR4CSF1RSMO | |
| SCHEMBL24721128 | 0.74 | FFAR4 (0.39) | FFAR4CSF1RSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | TRPV4 2057/4885FFAR4 25/4885CSF1R 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.